WebJun 8, 2024 · AITL is a rare subtype of peripheral T-cell lymphoma with rapid disease progression and poor prognosis. In the present study, the expected 1-, 2-, and 3-year survival rate was 72.2%, 49.6%, and 42.5%, respectively, and the median OS was 23 months (95% CI: 8.459~37.541). WebJun 6, 2016 · Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas. Angioimmunoblastic T-cell lymphoma (AITL) is a common subtype of PTCL, and patients with AITL typically have a poor prognosis with limited treatment options.
Outcomes and prognostic factors in angioimmunoblastic …
WebOct 19, 2024 · A 2024 in-vitro study stated that it is also associated with over 80% of angioimmunoblastic T-cell lymphoma (AITL). A 2014 review found that individuals with a family history of blood cancers, ... WebThe prognosis of AITL is poor compared with that of other forms of non-Hodgkin lymphoma, with a 5-year overall survival of 33% and a 5-year treatment failure–free … paramount builders
Long-Term Treatment with Romidepsin in Patients with Peripheral …
WebSurvival outcome of patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) who experience disease … WebMar 15, 2024 · Common signs and symptoms of AITL are non-painful enlarged lymph nodes, fluid accumulation, joint inflammation, weight loss, excessive night sweats, and low red blood cell counts When the skin is involved, a widespread erosion of the skin may be observed. The manifestation may be in the form of multiple macules or nodules. WebAngioimmunoblastic T-cell lymphoma (AITL) is a sub-type of peripheral T-cell lymphoma (PTCL) with a special characteristic appearance under the microscope and unique clinical symptoms. It is rare, comprising 10-15% of all T-cell lymphomas and only 1-3% of all non-Hodgkin lymphomas. Angioimmunoblastic T-cell Lymphoma By: Dr. Andrei Shustov paramount buffet